No connection

Search Results

ABBV vs NNNN

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
NNNN
Anbio Biotechnology
BEARISH
Price
$28.84
Market Cap
$1.27B
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
ABBV
163.63
NNNN
192.27
Forward P/E
ABBV
15.42
NNNN
--
P/B Ratio
ABBV
-146.66
NNNN
45.92
P/S Ratio
ABBV
6.5
NNNN
146.39
EV/EBITDA
ABBV
15.27
NNNN
--

Profitability

Gross Margin
ABBV
71.46%
NNNN
87.24%
Operating Margin
ABBV
35.5%
NNNN
59.09%
Profit Margin
ABBV
4.0%
NNNN
74.06%
ROE
ABBV
137.96%
NNNN
27.05%
ROA
ABBV
9.59%
NNNN
14.66%

Growth

Revenue Growth
ABBV
9.1%
NNNN
73.9%
Earnings Growth
ABBV
-88.7%
NNNN
--

Financial Health

Debt/Equity
ABBV
--
NNNN
--
Current Ratio
ABBV
0.72
NNNN
344.31
Quick Ratio
ABBV
0.47
NNNN
177.13

Dividends

Dividend Yield
ABBV
3.05%
NNNN
--
Payout Ratio
ABBV
490.15%
NNNN
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
NNNN BEARISH

The company exhibits a stable Piotroski F-Score of 5/9, but this fundamental stability is completely overshadowed by an extreme valuation disconnect. With a Graham Number of $1.46 and an Intrinsic Value of $1.05, the current price of $28.84 represents a massive speculative premium. While profitability margins and revenue growth are exceptional, the Price-to-Sales ratio of 146.39 and P/E of 192.27 are unsustainable. Combined with a bearish technical trend (0/100) and weak insider sentiment, the stock appears to be in a bubble phase.

Strengths
Exceptional profit margins (74.06%) and gross margins (87.24%)
Strong year-over-year revenue growth of 73.90%
Extremely high liquidity with a current ratio of 344.31
Risks
Severe overvaluation with a P/S ratio of 146.39
Massive gap between current price ($28.84) and Graham Number ($1.46)
Bearish technical trend (0/100) suggesting a loss of momentum

Compare Another Pair

ABBV vs NNNN: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and Anbio Biotechnology (NNNN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile